VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)

PHASE3CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

February 28, 2013

Study Completion Date

August 31, 2013

Conditions
Myopia, Pathological
Interventions
BIOLOGICAL

VEGF Trap-Eye (BAY86-5321)

1 intravitreal injection of the experimental drug, followed by monthly re-injections if needed

PROCEDURE

No Drug

Sham procedure NOT involving injection of any substance; patient´s eye is anesthetized and a syringe without needle gently pressed on the cornea

Trial Locations (20)

333

Taoyuan District

11217

Taipei

168751

Singapore

Unknown

Kowloon

466-8560

Nagoya

467-8602

Nagoya

279-0021

Urayasu

790-8524

Matsuyama

812-8582

Fukuoka

960-1295

Fukushima

606-8507

Kyoto

984-8560

Sendai

545-8586

Osaka

558-8558

Osaka

565-0871

Suita

520-2192

Ōtsu

113-8519

Bunkyo-ku

101-8309

Chiyoda-ku

160-8582

Shinjuku-ku

137 701

Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Bayer

INDUSTRY